Smith Thornton Advisors LLC Sells 80 Shares of Humana Inc. (NYSE:HUM)

Smith Thornton Advisors LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,904 shares of the insurance provider’s stock after selling 80 shares during the period. Smith Thornton Advisors LLC’s holdings in Humana were worth $737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Creative Financial Designs Inc. ADV increased its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the last quarter. Atwood & Palmer Inc. bought a new stake in Humana in the third quarter worth $29,000. Ashton Thomas Securities LLC bought a new stake in Humana in the third quarter worth $31,000. Your Advocates Ltd. LLP increased its position in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management bought a new stake in Humana in the second quarter worth $40,000. Institutional investors own 92.38% of the company’s stock.

Insiders Place Their Bets

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.29% of the stock is owned by company insiders.

Humana Stock Down 0.9 %

HUM opened at $280.20 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market cap of $33.74 billion, a P/E ratio of 24.82, a PEG ratio of 2.02 and a beta of 0.55. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $455.53. The business’s fifty day simple moving average is $274.33 and its 200 day simple moving average is $309.10.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities research analysts anticipate that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. Humana’s payout ratio is currently 31.36%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HUM shares. UBS Group reduced their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. Finally, Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $302.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.